原发性中枢神经系统淋巴瘤的特点及诊治的研究进展  

Research progress of clinical characteristics and diagnosis and treatment for primary central nervous system lymphoma

作　　者：封云 何翠影 王连静 李炜静 刘玮 刘丽宏[1] Feng Yun;He Cuiying;Wang Lianjing;Li Weijing;Liu Wei;Liu Lihong(Department of Hematology,Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,Hebei Province,China)

机构地区：[1]河北医科大学第四医院血液内科,石家庄050011

出　　处：《国际输血及血液学杂志》2021年第5期447-455,共9页International Journal of Blood Transfusion and Hematology

摘　　要：原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见且特异性结外非霍奇金淋巴瘤(NHL),其发病率呈逐年上升趋势,并且患者预后较差。近年来,随着对PCNSL分子遗传学发病机制研究的进一步深入,部分分子生物学标志物及基因突变被证实对PCNSL患者的诊断及预后判断具有指导意义。在以大剂量甲氨蝶呤(HD-MTX)为基础的传统治疗方案上,临床已根据相关生物学标志物及基因突变为靶标进行一系列靶向治疗的研究。为了探讨PCNSL的疾病特点并为其诊治提供参考,笔者拟就PCNSL患者的临床表现及诊断、新型分子生物学标志物、相关基因突变、治疗及预后方面的研究进展进行综述。Primary central nervous system lymphoma(PCNSL)is a rare and specific form of extra-nodal non-Hodgkin lymphoma(NHL).Morbidity of PCNSL patients shows an upward trend,and their prognosis is poor.In this context,pathogenesis of PCNSL molecular genetics has been further researched in recent years.Some molecular biological markers and gene mutations are comfirmed to be significant for diagnosis and prognosis of patients with PCNSL.A series studies of targeted therapy have been made combined with traditional high-dose methotrexate(HD-MTX)-based chemotherapy.In order to investigate disease characteristics of PCNSL and provide reference for its diagnosis and treatment,this article reviews research progress of clinical manifestations and diagnosis,new molecular biomarkers,related gene mutations,treatment and prognosis of PCNSL.

关 键 词：淋巴瘤 中枢神经系统 生物学标记 突变 分子靶向治疗 

分 类 号：R739.4[医药卫生—肿瘤]